Sildenafil (Generic) vs Vardenafil (Levitra/Staxyn): Real-World Evidence Comparison

What Are These Drugs and How Do They Work?

Both sildenafil and vardenafil block phosphodiesterase type 5 (PDE5), the enzyme that degrades cyclic GMP in penile smooth muscle. Blocking PDE5 prolongs the vasodilatory effect of nitric oxide released during sexual stimulation, allowing sufficient blood flow for an erection. Neither drug works without sexual arousal.

Shared Mechanism, Different Selectivity Profiles

The two molecules differ in their binding affinity for PDE5 relative to other PDE isoforms. Vardenafil has roughly 10-fold higher potency at PDE5 than sildenafil on a milligram-for-milligram basis, which is why the maximum approved dose of vardenafil (20 mg) is lower than sildenafil's (100 mg) [1]. Sildenafil also inhibits PDE6, an enzyme in retinal photoreceptors, more substantially than vardenafil does. That difference explains the classic blue-tinge or halo visual disturbance reported by roughly 3% of sildenafil users but <1% of vardenafil users [2].

Nitric Oxide Dependence

Both drugs are vasodilators that depend entirely on endogenous nitric oxide. Men with severe endothelial dysfunction, low testosterone, or significant neuropathy may respond poorly to either drug for that reason, not because of a difference between sildenafil and vardenafil specifically.

PubMed: Mechanism of PDE5 inhibition

Efficacy: Head-to-Head and Real-World Data

Direct head-to-head randomized controlled trials between sildenafil and vardenafil are relatively few, but pooled data from large placebo-controlled programs and cross-over studies consistently show comparable efficacy in the general ED population.

Landmark Trial Results

Goldstein et al. (NEJM, 1998, N=861) demonstrated that sildenafil produced successful intercourse in 69% of attempts vs. 22% for placebo across dose groups, with the 100 mg dose achieving up to 82% success [1]. The key vardenafil program reported by Porst et al. (Int J Impot Res, 2003, N=580) showed successful intercourse rates of 71 to 75% with vardenafil 10 to 20 mg vs. 45% placebo, with IIEF erectile function domain scores improving by approximately 7 to 8 points over baseline [2].

Those numbers are close enough that no clinician should declare one drug definitively superior based on trial data alone.

Cross-Over and Preference Studies

In crossover studies where men tried both agents, roughly 50 to 60% expressed a preference, usually driven by perceived faster onset with vardenafil or lower side-effect burden rather than a clear difference in achieving an erection. A 2003 pooled analysis (N=2,912, vardenafil across four Phase III trials) showed consistent improvements in all three domains of the IIEF regardless of ED severity or comorbidity, matching what was observed across the sildenafil clinical program [2].

Subgroup Populations

Men with type 2 diabetes represent a harder-to-treat subgroup because both vascular and neurogenic components contribute to their ED. Sildenafil showed approximately 50 to 59% successful-intercourse rates in diabetic men vs. 10 to 13% placebo in Goldstein's key trial. Vardenafil produces similar results in diabetic subgroups: a dedicated diabetic ED trial (N=452) showed successful-intercourse rates of 57 to 72% across the 10 mg and 20 mg vardenafil doses vs. 28% placebo [2]. Neither drug clearly outperforms the other in this population.

PubMed: Goldstein et al., NEJM 1998 PubMed: Porst et al., Int J Impot Res 2003

Onset and Duration: Practical Timing Differences

How Quickly Do They Work?

Sildenafil reaches peak plasma concentration (Tmax) in approximately 60 minutes under fasting conditions, though some men notice effect as early as 30 minutes. Vardenafil reaches Tmax in 30 to 60 minutes as well, but its higher PDE5 potency may translate to perceptible effect slightly sooner for some users. The orodispersible Staxyn formulation (10 mg) dissolves under the tongue, which may hasten absorption, though pharmacokinetic studies show Staxyn is not bioequivalent to standard Levitra tablets and should not be used interchangeably [3].

Duration of Effect

Both drugs are effective for roughly 4 to 5 hours in most men. Sildenafil's half-life is about 3 to 5 hours; vardenafil's is similar at 4 to 5 hours. Neither matches tadalafil (Cialis), which has a 17.5-hour half-life allowing 36-hour windows of opportunity. Men who want a longer window should consider tadalafil rather than switching between sildenafil and vardenafil.

FDA label: Staxyn (vardenafil HCl) orodispersible tablet

Food and Alcohol Interactions

The High-Fat Meal Problem With Sildenafil

This is one of the most clinically meaningful practical differences. High-fat meals delay sildenafil's Tmax by approximately 60 minutes and reduce peak plasma concentration (Cmax) by roughly 29% [4]. A man who takes sildenafil 50 mg after a steak dinner may experience a blunted, delayed response and incorrectly conclude the drug has "stopped working."

Vardenafil (standard tablet) is only modestly affected by food. A high-fat meal delays Tmax by 60 minutes as well but does not meaningfully reduce Cmax for the tablet formulation. The Staxyn orodispersible tablet, however, should NOT be taken with any liquid other than water, and taking it with a high-fat meal significantly reduces absorption [3].

Alcohol

Both agents cause some additive vasodilation with alcohol. Neither drug is absolutely contraindicated with moderate alcohol (up to two drinks), but excessive alcohol independently causes erectile failure regardless of which PDE5 inhibitor a man uses.

FDA label: Viagra (sildenafil citrate)

Side Effect Profiles: Where They Differ

Shared Side Effects

Headache (10 to 16%), flushing (10 to 12%), nasal congestion (3 to 4%), and dyspepsia (3 to 5%) occur at similar rates with both drugs. These are class effects from systemic PDE5 inhibition and vasodilation.

Vision: Sildenafil's Distinguishing Adverse Effect

Sildenafil's inhibition of PDE6 in retinal cells causes the blue-tinge chromopsia or light-haze disturbance seen in approximately 3% of men at the 100 mg dose. This effect is dose-dependent and transient, resolving within 2 to 4 hours. Vardenafil's greater selectivity for PDE5 over PDE6 means this side effect is rare (<1%) [2]. Men who specifically find the visual disturbance bothersome on sildenafil 100 mg are reasonable candidates for a trial of vardenafil.

QTc Prolongation: Vardenafil's Distinguishing Safety Signal

Vardenafil produces a small but measurable prolongation of the QTc interval (approximately 8 ms at the 10 mg dose in dedicated cardiac electrophysiology studies) [5]. Sildenafil does not carry this signal to the same degree. The FDA label for vardenafil therefore contraindicates co-administration with Class IA antiarrhythmics (quinidine, procainamide) and Class III antiarrhythmics (amiodarone, sotalol). Men with congenital long QT syndrome or those taking QT-prolonging medications should use sildenafil preferentially.

Nitrate Contraindication

Both drugs are absolutely contraindicated with any form of organic nitrate (nitroglycerin, isosorbide mononitrate, isosorbide dinitrate, amyl nitrite poppers). The combination can cause severe, refractory hypotension. This contraindication applies equally to both drugs.

PubMed: Porst et al., Int J Impot Res 2003, safety data

Cost and Accessibility

Sildenafil is available as a generic in the United States and most markets, bringing the per-tablet cost to $0.50, $3.00 depending on dose, pharmacy, and discount programs. Vardenafil became generically available in the US in 2018, but generic availability is still less widespread than sildenafil, and pricing typically runs $5, $20 per tablet without insurance or coupon assistance.

For most men without a clinical reason to prefer vardenafil, sildenafil's cost advantage is substantial over time. A 30-tablet monthly supply of generic sildenafil 50 mg can cost $20, $60 at major pharmacy discount programs. The same supply of generic vardenafil may cost two to four times more.

FDA: Generic drug approvals

Drug Interactions Beyond Nitrates

CYP3A4 Inhibitors

Both sildenafil and vardenafil are metabolized primarily by CYP3A4. Strong inhibitors of this enzyme (ketoconazole, ritonavir, clarithromycin, grapefruit juice in large quantities) substantially raise plasma levels of both drugs and require dose reduction. With ritonavir co-administration, sildenafil should not exceed 25 mg per 48 hours; the vardenafil label advises a maximum single dose of 2.5 mg per 24 hours with ritonavir [3][4].

Alpha-Blockers

Both drugs interact with alpha-adrenergic blockers (tamsulosin, terazosin, alfuzosin) used for benign prostatic hyperplasia, increasing hypotension risk. The interaction is somewhat more pronounced with vardenafil based on pharmacodynamic studies. Men on alpha-blockers should be stabilized on the alpha-blocker before starting either PDE5 inhibitor, and both should be started at the lowest dose.

FDA label: Levitra (vardenafil HCl)

Who Should Consider Vardenafil Over Sildenafil?

The following clinical decision framework reflects the HealthRX medical team's approach to selecting between these two agents, based on the evidence reviewed above and standard prescribing practice.

Prefer vardenafil (Levitra/Staxyn) when:

• The man consistently eats large meals before sexual activity and cannot adjust timing, making sildenafil's food sensitivity a practical problem.
• Bothersome visual side effects (blue tinge, photosensitivity) occur on sildenafil 100 mg and dose reduction to 50 mg does not resolve them.
• Faster perceived onset is clinically meaningful and the man is not a candidate for tadalafil.
• The cost difference is not a barrier.

Prefer sildenafil when:

• Cost is a primary consideration.
• The man takes Class IA or III antiarrhythmics (QTc concern with vardenafil).
• Congenital long QT syndrome is present.
• Generic availability matters for adherence.
• The man has already responded well to sildenafil at an appropriate dose.

Consider tadalafil (Cialis/generic) instead of either when:

• Spontaneity is the dominant concern (tadalafil daily 2.5 to 5 mg or 36-hour dosing window).
• The man takes alpha-blockers for BPH and wants the agent with the most established co-administration data.

Should You Switch From Sildenafil to Vardenafil?

The practical question most men ask is whether switching makes sense after sildenafil "stops working." The evidence suggests several points worth understanding before making that decision.

Why Sildenafil May Appear to Fail

True pharmacological non-response to sildenafil at 100 mg taken correctly (fasting, 60 minutes before activity, with adequate arousal) is relatively uncommon. Real-world sildenafil "failures" frequently involve [1][2]:

• Subtherapeutic dosing (taking 25 to 50 mg when 100 mg is indicated)
• Taking the drug after a high-fat meal
• Insufficient arousal or anxiety
• Unaddressed testosterone deficiency (men with total testosterone <200 ng/dL respond poorly to any PDE5 inhibitor without concurrent testosterone therapy)
• Progressive underlying vascular disease

A prescriber who simply switches a non-responder from sildenafil to vardenafil without investigating these factors is likely to produce a second non-responder.

When Switching Is Justified

Switching is reasonable in men who respond adequately but find specific sildenafil side effects unacceptable (visual disturbance being the clearest example) or whose lifestyle makes food timing consistently impractical. In those cases, the IIEF scores and intercourse success rates are close enough that a trial of vardenafil 10 mg (or 20 mg if needed) is clinically appropriate.

The American Urological Association 2018 guideline on erectile dysfunction states: "For men who do not respond to PDE5 inhibitors, re-evaluation of diagnosis, optimization of risk factors, and patient/partner education should occur before abandoning oral therapy." [5]

Practical Switching Protocol

If a prescriber and patient agree to try vardenafil after sildenafil:

1. Start vardenafil at 10 mg, taken 30 to 45 minutes before activity, on an empty stomach or after a light meal.
2. Attempt at least 4 separate occasions before judging response (consistent with AUA guidance that a single trial is insufficient).
3. If 10 mg produces partial response, increase to 20 mg.
4. Reassess testosterone, blood pressure, and any concurrent medications at the same visit.

PubMed: AUA ED Guideline reference

Special Populations

Men With Diabetes

Both agents show roughly equivalent efficacy in diabetic ED, with success rates 15 to 25 percentage points lower than in non-diabetic populations [2]. The ADA Standards of Medical Care in Diabetes recommend optimizing glycemic control as a first step because hyperglycemia independently impairs endothelial nitric oxide synthesis. Switching between sildenafil and vardenafil without addressing glycemic control is unlikely to produce meaningful improvement.

ADA Standards of Medical Care 2024

Men After Radical Prostatectomy

Nerve-sparing prostatectomy causes temporary or permanent cavernous nerve damage that substantially reduces PDE5 inhibitor response rates. Studies show 30 to 60% of nerve-sparing prostatectomy patients respond to sildenafil at 100 mg; vardenafil data in this group show similar response rates. Neither agent is clearly superior. Penile rehabilitation protocols using daily low-dose PDE5 inhibition (sildenafil 25 mg nightly or tadalafil 5 mg daily) are the more relevant clinical consideration in this group.

Men With Cardiovascular Disease

The Princeton III Consensus guidelines (updated 2012) classified men with ED and cardiovascular disease into low, intermediate, and high risk categories. Both sildenafil and vardenafil fall under the same risk-stratification framework. The absolute contraindication is nitrate co-use. For low-risk patients (controlled hypertension, mild stable angina, successful revascularization), both drugs are considered safe to prescribe.

PubMed: Princeton Consensus reference

Dosing Reference Table

| Parameter | Sildenafil (Generic/Viagra) | Vardenafil (Levitra) | Vardenafil (Staxyn ODT) | |---|---|---|---| | Available doses | 25, 50, 100 mg | 5, 10, 20 mg | 10 mg only | | Starting dose | 50 mg | 10 mg | 10 mg | | Max dose | 100 mg | 20 mg | 10 mg (not to exceed) | | Timing before activity | 30 to 60 min | 25 to 60 min | 25 to 60 min | | Food effect on absorption | High-fat meal reduces Cmax ~29% | Minimal (tablet) | Significant (do not take with food) | | Half-life | ~3 to 5 hours | ~4 to 5 hours | ~4 to 5 hours | | QTc signal | Minimal | Small (8 ms at 10 mg) | Small (8 ms equivalent) | | Visual side effects | ~3% at 100 mg | <1% | <1% |

What Real-World Prescribing Data Show

Survey and claims data from US pharmacy records consistently show sildenafil as the dominant PDE5 inhibitor by volume, accounting for approximately 60 to 65% of all PDE5 inhibitor prescriptions, followed by tadalafil at 25 to 30%, with vardenafil comprising roughly 5 to 10% of the market [6]. This reflects cost and availability differences as much as any clinical preference. Deriving a conclusion about clinical superiority from market share alone is not valid. Vardenafil's prescribing frequency is disproportionately lower relative to its comparable efficacy, suggesting cost and brand familiarity drive selection more than clinical outcomes.

FDA: Drug use trends and PDE5 class